From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects

Overview

This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on or off their spinal cord stimulators for two week intervals up to six weeks after enrollment, and on the final day of study participation, for one hour intervals, in a multi-crossover design. In a subset of patients we will also perform combined positron emission tomography/magnetic resonance imaging at baseline, week 2 and week 4.

Detailed description

The fundamental hypothesis for this study is that spinal cord stimulators modulate the excitability of primary afferent neurons to reduce pain, and that these changes can be detected by measurement of axonal excitability. For the primary outcome, the study investigators will leverage the sensitivity and reproducibility of threshold tracking nerve conduction studies to detect changes in the excitability of thickly myelinated nerve fibers. The study investigators will use microneurography to record directly from primary nociceptive afferents. Finally, the study investigators will perform plasma inflammatory cytokine profiles to measure changes due to spinal cord stimulators. By correlating changes in outcome measurements with subject pain levels during therapeutic versus minimal spinal cord stimulators settings, this study will determine which effects may be mechanistically relevant and which are unrelated to reduction in pain. Thus, this study will use robust, reproducible techniques to define the peripheral, central, and systemic effects of spinal cord stimulators.

Interventions

• Other Spinal Cord Stimulator Set to Minimal/No Stimulation Setting
  Patients in this intervention group will have their spinal cord stimulator turned off or to the minimal settings possible.
• Other Usual Care
  Patients in this intervention group will have their spinal cord stimulator turned on to their usual stimulation settings.
• Drug Positron Emission Tomography / Magnetic Resonance Imaging
  Patients with imaging compatible devices will undergo positron emission tomography/magnetic resonance imaging at three time points during the study. This imaging involves administration of the \[11C\]PBR28 radioligand, which is an investigational drug. Only a subset of patients who have 3 Tesla magnetic resonance imaging compatible stimulators will undergo this imaging.

Primary outcome measures

• Supraexcitability [Time frame: From baseline (enrollment) to six weeks]

Eligibility criteria

Inclusion criteria

• Aged 18 to 80
• Capable of providing informed consent and following trial procedures, including capacity to complete self-reported measures of pain, function, and other outcomes
• Stably implanted spinal cord or dorsal root ganglion stimulator
• Device is to treat back/radicular lower extremity pain or neck/arm pain
• Device with a paresthesia-free setting

Exclusion criteria

• Patients who are not on a stable dose of opioids or are on a stable dose greater than 100 MME/day per day within the two months prior to enrollment, or those who are unwilling to maintain a stable dose of opioids throughout the duration of the study
• The investigator concludes that the participant is unable to differentiate back or neck/arm pain from other pains
• Systemic or psychiatric illness that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial
• Other factor that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial or tolerate the study procedures

Dropout Criteria for Optional Imaging

• Stimulation device is not 3 Tesla magnetic resonance imaging compliant
• Contraindications to magnetic resonance imaging and/or positron emission tomography scanning (including presence of a cardiac pacemaker or pacemaker wires, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)
• Pregnant or breastfeeding
• Participants with a low affinity binder phenotype based off testing for the Ala147Thr polymorphism.
• Current or recent use of benzodiazepines (except for alprazolam, clonazepam, and lorazepam). Recent use will be defined based off the benzodiazepines half-life, such that patients who stopped taking the medication at least five half-lives ago will be considered eligible for scanning.
• Subjects who have exceeded (or would exceed if they were to participate) the yearly amount of allowable radiation, as defined by the Radiation Safety Committee
• In the opinion of the investigators, unable to safely participate in this study and/or provide reliable data (e.g., unlikely to remain still during the imaging procedures).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Crossover

Masking

Quadruple blind

Primary purpose

Other

Study locations

United States · 3 centers

• Massachusetts General Hospital — Boston
• Beth Israel Deaconess Medical Center — Boston
• Brigham and Women's Hospital — Boston

Identifiers

NCT: NCT05661903 · 2022P001803 · 1RM1NS128741-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗